Investor Relations

BCR (Common Stock)
ExchangeNYSE (US Dollar)
Change (%) Stock is Down 3.68 (1.86%)
Data as of 08/31/15 4:06 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Reports
Download Documentation2015 Proxy Statement
Download Documentation2014 Annual Report
Related Links
Corporate Governance
Contact the Bard Board of Directors
Recent NewsMore >>
08/03/15CMS Approves Add-on Payment for Lutonix® Drug-Coated Balloon for Inpatient Use
MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 3, 2015-- C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment for the Lutonix® Drug-Coated Balloon (DCB) under the Medicare hospital inpatient prospective payment system. The purpose of the reimbursement is to help cover additional cost to U.S. hospitals for treating Medicare beneficiaries with the Lutonix® D... 
Printer Friendly Version
07/23/15Bard Announces Second Quarter Results
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 23, 2015-- C. R. Bard, Inc. (NYSE:BCR) today reported 2015 second quarter financial results. Second quarter 2015 net sales were $859.8 million, an increase of 4 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, second quarter 2015 net sales increased 8 percent over the prior-year period. For the second quarter 2015, net sales in the U.S. were $592.0 milli... 
Printer Friendly Version
07/01/15Bard to Host Earnings Conference Call on July 23, 2015
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 1, 2015-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will host a conference call on Thursday, July 23, 2015 at 5:00 PM EDT, to discuss the company’s second quarter 2015 operating results, and to provide financial guidance for the third quarter of 2015. Bard is scheduled to issue an earnings press release after the market closes on July 23, 2015. A live audio webcast of Bard's investor conference w... 
Printer Friendly Version
06/25/15 The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 25, 2015-- C. R. Bard, Inc. (NYSE:BCR) today announced the publication of results from the LEVANT 2 study in the June 24, 2015 online issue of The New England Journal of Medicine. Results from LEVANT 2 demonstrated superior primary patency for Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® DCB) over standard percutaneous transluminal angioplasty (PTA), as well as safety consistent with standard PTA... 
Printer Friendly Version
Selected SEC Filings
Filing DateForm
07/24/1510-Q Download SEC Filing to Adobe PDF Download XBRL Content
04/24/1510-Q Download SEC Filing to Adobe PDF Download XBRL Content
02/18/1510-K Download SEC Filing to Adobe PDF Download XBRL Content
10/23/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
07/25/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever C. R. Bard, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.